Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. ...
Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
inControl Diabetes Center, Honolulu, Hawaii, United States
Sansum Diabetes Research Institute, Santa Barbara, California, United States
Yale University, New Haven, Connecticut, United States
Division of Endocrinology, Diabetes, Clinical Nutrition & Metabolism, University Hospital Berne, Switzerland, Berne, Switzerland
Novo Nordisk Investigational Site, Truro, United Kingdom
Novo Nordisk Investigational Site, Beijing, Beijing, China
Novo Nordisk Investigational Site, Vinnytsia, Ukraine
Valley Endocrine, Fresno, Fresno, California, United States
Physicians East, Greenville, North Carolina, United States
Diabetes and Endocrine Associates, La Mesa, California, United States
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
Aventiv Research, Columbus, Ohio, United States
Dallas Diabetes Endocrine Center, Dallas, Texas, United States
Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong
Novo Nordisk Investigational Site, Fuzhou, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.